Servier

Boston – November 06, 2026 -- Servier will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, held November 12-15 in Philadelphia. The package covers both of its glioma therapies: VORANIGO (vorasidenib) in IDH-mutant glioma and OJEMDA (tovorafenib) in BRAF-altered pediatric low-grade glioma (pLGG).

Four-year FIREFLY-1 data to cover retreatment after progression in pLGG

One oral presentation will deliver updated results from the four-year follow-up of the Phase 2 FIREFLY-1 study of OJEMDA in relapsed or refractory BRAF-altered pLGG. The analysis includes data on post-treatment observation and on retreatment with OJEMDA after disease progression.

BOULDER, Colo. – November 04, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) reported third-quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, driven by a $1.348 billion gain on the sale of its sevasemten program and muscular dystrophy business to Servier. In the same period of 2025, the company posted a net loss of $40.7 million, or $0.39 per share.

Servier sale delivers $1.396 billion in upfront cash

The transaction closed in July 2026. Edgewise received $1.396 billion in upfront cash at closing. The reported gain includes consideration recognized at closing, among it amounts tied to the general indemnification arrangement. It is stated net of the carrying value of transferred assets, transaction costs and consideration allocated to transition services. Income tax expense associated with the transaction partly offset the gain in net income.

Boston – October 19, 2026 -- Servier has dosed the first patients in EMBLEM-1, the pivotal Phase 2 cohort of its Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in aggressive adenoid cystic carcinoma (ACC), a cancer with no FDA-approved systemic treatment.

Emi-Le is an investigational antibody drug conjugate (ADC) directed against B7-H4. The cohort is enrolling under trial identifier NCT05377996.

EMBLEM-1 uses objective response rate per RECIST 1.1 as its primary endpoint

The trial will measure the percentage of patients who achieve a best overall response of confirmed complete response or partial response. It will also evaluate the safety of Emi-Le in ACC.

Barcelona – September 30, 2026 -- Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, part of a global push to build an AI-ready data foundation for its commercial and medical teams.

Servier scales AI infrastructure after prior success with Veeva Link Key People

The French pharmaceutical company, governed by a Foundation, is harmonizing customer reference data globally to create a unified semantic layer that connects with Veeva Link. Liam Hanrahan, director of world operations excellence at Servier, said the move goes beyond process improvement, calling it the construction of a global data foundation designed to redefine how the company operates and scale AI across its affiliates.

Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.

ISM1354 improves on Insilico's earlier GIPR candidate ISM0676

South San Francisco, Calif. – September 13, 2026 -- IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase 3 trial testing darovasertib combined with crizotinib as adjuvant therapy for primary uveal melanoma, targeting a disease segment with no approved systemic treatment options.

Trial design pairs oral PKC and cMET inhibitors for high-risk patients post-local therapy

OptimUM-11 will enroll approximately 450 patients who have completed local therapy for primary uveal melanoma and face elevated risk of metastatic recurrence. Patients will be randomized 1:1 to receive darovasertib plus crizotinib for 12 months or to observation, regardless of HLA status. The primary endpoint is relapse-free survival.